What is NAC good for, and what does the evidence actually show?

This entry is part of the Nutri Tailor Health Reference Library — cited research on supplements, nutrients and adjacent areas of health.

Summary

NAC is a stable form of cysteine, the rate limiting ingredient for glutathione, the cell's main antioxidant, and raising glutathione is the mechanism behind nearly every claimed benefit. The firmest supplement evidence is respiratory: a meta-analysis found long term oral NAC cut chronic bronchitis and COPD flare ups by roughly a quarter, with about 1200 mg a day needed where COPD is confirmed. Hospital use of intravenous acetylcysteine after paracetamol overdose is an established clinical fact, not a reason to take capsules. Research doses run 600 to 1800 mg a day and side effects are mostly mild digestive upset. At 375 mg per capsule, two capsules reach 750 mg and the sulphur smell in the bottle is normal.

How it works

Glutathione synthesis is limited by the availability of cysteine, and NAC is a delivery vehicle for cysteine that survives the gut and enters cells. Higher intracellular glutathione improves the cell's ability to neutralise reactive oxygen species and supports phase two liver conjugation pathways. NAC also breaks disulphide bonds in mucus, thinning it, which is the separate mucolytic mechanism behind the respiratory trial results. Claims beyond these two mechanisms, glutathione support and mucolysis, generally run ahead of the human evidence.

Effective dose

Respiratory trials used 600 mg a day in chronic bronchitis, and roughly 1200 mg a day where COPD was confirmed by lung function testing. Trials in other areas ran 600 to 1800 mg a day, with 2400 mg well tolerated in short studies. At 375 mg per capsule, one capsule is a maintenance intake, two capsules reach 750 mg, and four capsules reach 1500 mg, which covers the trial range. There is no UK reference intake because NAC is not an essential nutrient; the body normally gets cysteine from dietary protein.

Forms compared

NAC is one molecule; the buying choices are capsule, effervescent and powder. Capsules avoid the strong sulphur taste that puts most people off powders. The acetyl group is what makes NAC worth buying over plain L-cysteine, which is unstable and poorly absorbed; NAC survives digestion and converts to cysteine inside cells. Sustained release versions exist but the outcome trials used standard oral NAC, so there is no evidence case for paying more. A 375 mg vegetarian capsule is a practical building block for the 375 to 1500 mg range.

Timing

NAC absorbs adequately with or without food, though taking capsules with a meal reduces the mild nausea a minority experience on an empty stomach. Trials dosed once or twice daily; at 1200 mg a day the studies typically split 600 mg morning and evening. There is no evening alertness issue and no meaningful clock time effect, so the practical rule is simply consistency, attached to an existing meal habit.

Safety profile

Oral NAC has decades of use and a clean record at supplement doses, with mild digestive upset and nausea the main complaints. The strong sulphur smell on opening a bottle is the molecule itself, not degradation. Very high intravenous doses in hospital settings carry reaction risks that do not translate to oral capsules. The sensible ceiling from the trial literature is around 1800 mg a day for self directed use, with anything higher belonging in a clinical conversation. Anyone with asthma should start cautiously, as inhaled and high dose NAC has occasionally triggered bronchospasm in that group.

Special populations

Pregnancy and breastfeeding lack adequate supplement safety data, so NAC is best avoided in both without clinical advice. People with asthma should start at low doses given occasional bronchospasm reports. Anyone on nitrate drugs for angina or on anticoagulants needs a prescriber conversation first. People with a history of stomach ulcers should take NAC with food, as it can irritate the stomach lining at higher doses.

Interactions

NAC has one clinically established interaction: activated charcoal binds it, a hospital scenario rather than a supplement one. Two cautions matter for supplement users. Nitroglycerin and related nitrate drugs for angina can interact with NAC to produce headaches and low blood pressure, so anyone on nitrates should involve their prescriber. And because NAC thins mucus and has mild blood thinning activity in some reports, people on anticoagulants should mention NAC to their prescriber. Among supplements, NAC is often paired with glycine, the other glutathione building block, with no reported problems.

Guideline positions

No UK dietary reference exists for NAC. The respiratory evidence is anchored by a meta-analysis in the European Respiratory Review reporting roughly a quarter fewer flare ups with long term oral NAC. The pharmacology is anchored by a major review in Pharmacology and Therapeutics on the glutathione conversion requirement, and a 2021 review in Antioxidants summarising the human evidence. NHS clinical use of acetylcysteine is a hospital matter and sits outside supplement guidance.

Practical framework

NAC is most rational for three situations. People with recurring winter chest trouble and heavy mucus have the most direct trial evidence at 600 mg a day, alongside a GP conversation if symptoms are new or worsening. People supporting glutathione status, particularly with low protein intakes, have a solid mechanistic case at 375 to 750 mg a day. Anyone chasing the higher dose trial territory around 1200 mg a day should be doing so for a defined reason over a defined period. A fair test is 8 to 12 weeks against the symptom you started with. The stocked option is a 375 mg capsule at nutritailor.co.uk/products/n-acetyl-cysteine.

Common misconceptions

The paracetamol overdose story is about intravenous hospital doses given under monitoring; keeping NAC capsules at home for that purpose is dangerous thinking, because overdose needs A&E, not a supplement. NAC was never banned in the UK; regulatory noise about NAC came from the United States and did not change UK availability. Raising glutathione is not the same as detoxing in the marketing sense; the molecule supports the liver's existing chemistry rather than flushing anything out. And the sulphur smell is normal, not a bad batch.

Sources

Cazzola M, Calzetta L, Page C, et al 2015. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. European Respiratory Review. PMID: 26324807
Rushworth GF, Megson IL 2014. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacology and Therapeutics. PMID: 24080471
Tenorio MCDS, Graciliano NG, Moura FA, de Oliveira ACM, Goulart MOF 2021. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel). PMID: 34208683
StatPearls 2024. N-Acetylcysteine, StatPearls. StatPearls Publishing, NCBI Bookshelf.

Back to nac overview